Use of a thromboxane receptor antagonist in pregnancy-induced hypertension

摘要

The use of a compound of formula (1 IMAGE wherein R1 is a H or methyl; X is cis or trans -CH=CH- or -CH2CH2-, m is 2, 3 or 4 and n is 1; or X is trans -CH=CH-, m is zero and n is 3; Y is a saturated heterocyclic amino group (attached to the cyclopentane ring via the nitrogen atom) which a has 5-8 ring members; Alk is a straight or branched C1-5 alkyl; l is zero or 1; p is zero, 1, 2, 3 or 4; R2 is OH, -OCOR3, -CO2R3, -CONR3R4, -SO2NR3R 4, -NHCOR3, -NH3, -NHSO2R5, -SO2R5, -SR5, -NR3R4, -COR5, NHCONR3R4 or -NHCSNH2; R3, and R3aand R4 are each H or a C1-4 alkyl or C7-10 aralkyl group; and R5 is a C1-4 alkyl group; or a physiologically acceptable salt, solvate or cyciodextrin complex thereof in the manufacture of medicaments for the therapy or prophylaxis of conditions associated with vasoconstriction and/or platelet aggregation in the uteroplacental circulation and/or excessive synthesis of thromboxane A2 in a pregnant female subject.